Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1908 - An insight on Head and neck cancer management in China

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Yang Xiaoshi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

Y. Xiaoshi1, D. Weiyi2

Author affiliations

  • 1 Department Of Epidemiology, China Medical University, 110001 - Shenyang/CN
  • 2 Head And Neck Cancer Center, Stomatology Hospital of China Medical University, 110001 - Shenyang/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1908

Background

As no Chinese data has evaluated the oncologists’ strategy for treatment and management of the head and neck cancer (HNC), this survey investigated Chinese oncologists’ treatment strategy in HNC.

Methods

This survey was conducted during October 2017 to January 2018 in 100 randomly selected tertiary Chinese hospitals from 21 cities. The plan was to include 300 non-randomly selected Chinese oncologists to know their responses on HNC. The investigating stages included: development of a questionnaire after consulting 9 experts in HNC; execution of a pre-test by 40 oncologists from 5 cities; reliability and validity evaluation followed by finalisation of the questionnaire; and conduct of formal investigation with oncologists. Results for all evaluations were presented as percentages.

Results

Of the 296 questionnaires received, 272 were considered valid. Among valid respondents, 65.1% oncologists reported nasopharyngeal carcinoma as the most common HNC, followed by laryngeal/hypopharyngeal (22.1%) carcinoma. 71.3% oncologists acknowledged having a multidisciplinary team for HNC treatment in their hospitals. Prescribed regimens for recurrent/metastatic HNC included taxane + platinum (TP), taxane-cisplatin-5fluorouracil (TFP), PF, TF and others (45.2%, 27.9%, 21%, 2.2% and 3.7%). Oncologists (77.6%) add target therapy to chemotherapy as the first line therapy in recurrent/metastatic cancer. For locally advanced HNC, anti-EGFR would be preferred by 84.2% oncologists. 39.0% oncologists reported considering inclusion of targeted therapy at combined radical radiotherapy and chemotherapy stage. HPV was believed to be associated with HNC prognosis by 72.0% oncologists; 1.9% oncologists disagreed and 26.1% were unsure. HPV testing rate was 67.3%. The reasons for not testing HPV were immature technical conditions (41.2%), no impact on treatment (40.8%), no consent by patients (25.0%) and low HPV incidence in Chinese HNC patients (18.01%).

Conclusions

In conclusion, oncologists in China have not fully followed international guidelines of HNC which might be due to practical considerations. These findings will provide future education for HNC management.

Clinical trial identification

Legal entity responsible for the study

China Medical University

Funding

Merck Serono Co. Ltd, Beijing, China.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.